4basebio plc (4BB), the UK-listed biotechnology company, has received a major shareholding notification confirming that Wilhelm K. T. Zours, based in Heidelberg, Germany, held 32.033704% of the company's voting rights as of 9 November 2026. The disclosure, filed with 4basebio on 11 November 2026 and completed on 12 November 2026, was triggered by an event changing the breakdown of voting rights. The position has decreased from the previously notified level of 33.010596%, a movement investors in the genomics-focused biotech will be watching closely.

Key Points

  • 4basebio plc (4BB), ISIN GB00BMCLYF79, is a UK-listed biotechnology company
  • Wilhelm K. T. Zours disclosed a 32.033704% total voting rights position in 4basebio plc, down from a previously notified 33.010596%
  • The threshold was crossed on 9 November 2026, with the issuer notified on 11 November 2026; 5,133,066 voting rights are held directly
  • Investors should watch whether further changes to Zours's position trigger additional TR-1 notifications

Wilhelm Zours Holds 5,133,066 Direct Voting Rights in 4basebio Following November 2026 Event

According to the TR-1 standard notification form, Wilhelm K. T. Zours holds all 5,133,066 voting rights directly, representing 32.033704% of 4basebio plc's total voting rights. No voting rights are held through financial instruments, meaning the entire position is composed of shares under ISIN GB00BMCLYF79. The notification was prompted by an event that altered the breakdown of voting rights rather than an outright purchase or disposal of shares, though the precise nature of that event is not detailed further in the announcement. The completed disclosure originates from Heidelberg, Germany, where Zours is registered.

Zours Controls 4basebio Stake Across Five Intermediary Entities Including 2invest AG and SPARTA Invest AG

The notification sets out the full chain of controlled undertakings through which Zours's aggregate position is maintained. The largest single component is held via 2invest AG, accounting for 13.910942% of voting rights, followed by SPARTA Invest AG at 8.435608%, Latonba AG at 5.030375%, and DELPHI Unternehmensberatung Aktiengesellschaft at 3.984260%. Additional entities listed in the chain include VV Beteiligungen Aktiengesellschaft, Deutsche Balaton Aktiengesellschaft, and SPARTA AG, though specific percentage figures for these three were not disclosed in the announcement beyond their inclusion in the chain.

Voting Stake Declines from 33.01% to 32.03%, Marking a Shift in Zours's 4basebio Position

Comparing the current notification against the previous filing, Zours's aggregate voting rights have fallen from 33.010596% to 32.033704%, a reduction of approximately 0.977 percentage points. This movement crossed a notifiable threshold under UK Disclosure Guidance and Transparency Rules, requiring the formal TR-1 submission. As a substantial shareholder commanding roughly one-third of 4basebio's voting rights, Zours remains the dominant individual stakeholder in the company. Any further changes to this position that cross a reporting threshold would require an additional disclosure to the market.